Literature DB >> 33755711

Developing the Pneumonia-Optimized Ratio for Community-acquired pneumonia: An easy, inexpensive and accurate prognostic biomarker.

Vinícius Ferraz Cury1, Lucas Quadros Antoniazzi1, Paulo Henrique Kranz de Oliveira1, Wyllians Vendramini Borelli2, Sainan Voss da Cunha1, Guilherme Cristianetti Frison1, Enrico Emerim Moretto1, Renato Seligman1,3.   

Abstract

INTRODUCTION: Community-acquired pneumonia (CAP) is still a major public health problem. Prognostic scores at admission in tertiary services may improve early identification of severity and better allocation of resources, ultimately improving survival. Herein, we aimed at evaluating prognostic biomarkers of CAP and a Pneumonia-Optimized Ratio was created to improve prognostic performance.
METHODS: In this retrospective study, all patients with suspected Community-acquired pneumonia aged 18 or older admitted to a public hospital from January 2019 to February 2020 were included in this study. Blood testing and clinical information at admission were collected, and the primary outcome was overall survival. CURB-65 scores and prognostic biomarkers were measured, namely Neutrophil-to-Lymphocyte Cell Ratio (NLCR), Platelet to Lymphocyte ratio (PLR), Monocyte to Lymphocyte Ratio (MLR). A Pneumonia-Optimized Ratio (POR) score was created by selecting the biomarker with larger accuracy (NLCR) and multiplying it by the patients' CURB-65 score. Multivariate regression model was performed and ROC curves were created for each biomarker.
RESULTS: Our sample consisted of 646 individuals (median 66 years [IQR, 18-103], 53.9% females) with complete blood testing at the time of admission. Patients scored 0-1 (323, 50%), 2 (187, 28.9%), or 3 or above (122, 18.9%) in the CURB-65, and 65 (10%) presented the primary outcome of death. POR exhibited the highest Area Under Curve (AUC) in the ROC analysis (AUC = 0.753), when compared with NLCR (AUC = 0.706), PLR (AUC = 0.630) and MLR (AUC = 0.627). POR and NLCR presented increased crude mortality rate in the fourth quartile in comparison with the first quartile, and the fourth quartile of NLCR had more days of hospitalization than the first quartile (11.06±15.96 vs. 7.02±8.39, p = 0.012).
CONCLUSION: The Pneumonia-Optimized Ratio in patients with CAP showed good prognostic performance of mortality at the admission of a tertiary service. The NLCR may also be used as an estimation of days of hospitalization. Prognostic biomarkers may provide important guidance to resource allocation in resource-limited settings.

Entities:  

Year:  2021        PMID: 33755711      PMCID: PMC7987181          DOI: 10.1371/journal.pone.0248897

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  26 in total

1.  Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study.

Authors:  W S Lim; M M van der Eerden; R Laing; W G Boersma; N Karalus; G I Town; S A Lewis; J T Macfarlane
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

2.  The Neutrophil to Lymphocyte Ratio Is Superior to Other Inflammation-Based Prognostic Scores in Predicting the Mortality of Patients with Pneumonia.

Authors:  Yuichiro Shimoyama; Osamu Umegaki; Satsuki Inoue; Tomoyuki Agui; Noriko Kadono; Toshiaki Minami
Journal:  Acta Med Okayama       Date:  2018-12       Impact factor: 0.892

3.  Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.

Authors:  Seema Jain; Wesley H Self; Richard G Wunderink; Sherene Fakhran; Robert Balk; Anna M Bramley; Carrie Reed; Carlos G Grijalva; Evan J Anderson; D Mark Courtney; James D Chappell; Chao Qi; Eric M Hart; Frank Carroll; Christopher Trabue; Helen K Donnelly; Derek J Williams; Yuwei Zhu; Sandra R Arnold; Krow Ampofo; Grant W Waterer; Min Levine; Stephen Lindstrom; Jonas M Winchell; Jacqueline M Katz; Dean Erdman; Eileen Schneider; Lauri A Hicks; Jonathan A McCullers; Andrew T Pavia; Kathryn M Edwards; Lyn Finelli
Journal:  N Engl J Med       Date:  2015-07-14       Impact factor: 91.245

4.  Neutrophil-to-Lymphocyte Ratio in Adult Community-Acquired Pneumonia Patients Correlates with Unfavorable Clinical Outcomes.

Authors:  Yan L Ge; Hai F Zhang; Qian Zhang; Xiao Y Zhu; Cong H Liu; Nan Wang; Jia B Zhang; Hao Chen; Yi Chen; Wen Q Li; Zhen Z Li; Ai S Fu; Hong Y Wang
Journal:  Clin Lab       Date:  2019-05-01       Impact factor: 1.138

5.  Lymphocytopenia and neutrophil-lymphocyte count ratio predict bacteremia better than conventional infection markers in an emergency care unit.

Authors:  Cornelis P C de Jager; Paul T L van Wijk; Rejiv B Mathoera; Jacqueline de Jongh-Leuvenink; Tom van der Poll; Peter C Wever
Journal:  Crit Care       Date:  2010-10-29       Impact factor: 9.097

6.  The association between the neutrophil-to-lymphocyte ratio and mortality in critical illness: an observational cohort study.

Authors:  Justin D Salciccioli; Dominic C Marshall; Marco A F Pimentel; Mauro D Santos; Tom Pollard; Leo Anthony Celi; Joseph Shalhoub
Journal:  Crit Care       Date:  2015-01-19       Impact factor: 9.097

Review 7.  New Biomarkers and Diagnostic Tools for the Management of Fever in Low- and Middle-Income Countries: An Overview of the Challenges.

Authors:  Camille Escadafal; Christian Nsanzabana; Julie Archer; Violet Chihota; William Rodriguez; Sabine Dittrich
Journal:  Diagnostics (Basel)       Date:  2017-07-21

8.  Community-acquired pneumonia: challenges of the situation in Brazil.

Authors:  Mauro Gomes
Journal:  J Bras Pneumol       Date:  2018 Jul-Aug       Impact factor: 2.624

9.  Eosinophil count and neutrophil-lymphocyte count ratio as prognostic markers in patients with bacteremia: a retrospective cohort study.

Authors:  Roser Terradas; Santiago Grau; Jordi Blanch; Marta Riu; Pere Saballs; Xavier Castells; Juan Pablo Horcajada; Hernando Knobel
Journal:  PLoS One       Date:  2012-08-09       Impact factor: 3.240

Review 10.  Evolving Understanding of the Causes of Pneumonia in Adults, With Special Attention to the Role of Pneumococcus.

Authors:  Daniel M Musher; Michael S Abers; John G Bartlett
Journal:  Clin Infect Dis       Date:  2017-10-30       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.